Ron Cohen

Ron Cohen, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Acorda Therapeutics Inc and Dyax Corp. Over a trading history stretching from 15 February 2006 to 17 March 2023, the count stands at 685 filings.

In open-market terms, that means 3 purchases worth €316k on one side and 628 sales worth €23.5M on the other. Taken together, the sales exceed the purchases by €23.2M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 20 share grants and 32 option exercises. 2023 to date brings 2 purchases and no sales.

A typical purchase (the median) is worth €6,124. None of the 3 purchases we analysed coincided with buying by another insider of the same company within 30 days.

The latest filing, published on 20 March 2023, reports an open-market purchase of €6,124 in Acorda Therapeutics Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.